The Europe IVD Raw Material Market was valued at $2189.9 Million in 2026 and projected to reach to $3241.7 Million by 2031, representing a compound annual growth rate of 8.2%. Europe's IVD raw material market is positioned for sustained growth through 2031, driven by an aging population requiring increased diagnostic testing and elevated healthcare spending across the region.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe's IVD raw material market is valued at $2,189.9 million in 2026, with significant growth projected to $3,241.7 million by 2031, representing an 8.2% CAGR that outpaces the global average of 7.7%.
Europe's aging demographic profile is a key growth driver, increasing demand for diagnostic testing and in vitro diagnostic components across hospitals, laboratories, and point-of-care settings.
Strong regulatory frameworks and European support for diagnostic innovation create a favorable environment for IVD raw material manufacturers and suppliers operating in the region.
Europe maintains a mature and well-established IVD raw material market with advanced healthcare infrastructure, high diagnostic adoption rates, and significant investment in healthcare technology.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Supplies antibodies, antigens, recombinant proteins, enzymes, membranes, and other critical raw materials used in the development of immunoassays, molecular diagnostics, and point-of-care tests. | Enables high assay sensitivity and specificity, ensures consistent test performance, and supports scalable diagnostic manufacturing. |
|
|
Provides a broad portfolio of antibodies, proteins, enzymes, nucleic acids, and specialty reagents for diagnostic assay development and commercialization. | Supports reliable assay development, improves diagnostic accuracy, and accelerates time-to-market for IVD manufacturers. |
|
|
Develops and manufactures diagnostic-grade antibodies, antigens, and assay components for immunodiagnostic and rapid testing applications. | Enhances assay performance, ensures batch-to-batch consistency, and supports high-quality diagnostic outcomes. |
|
|
Offers recombinant proteins, antibodies, immunoassay reagents, and molecular diagnostic raw materials for clinical and research diagnostic applications. | Provides high analytical sensitivity, supports biomarker detection, and enables development of advanced diagnostic tests. |
|
|
Supplies integrated raw material solutions including antibodies, antigens, enzymes, and detection reagents for immunoassays and point-of-care diagnostics. | Facilitates cost-effective assay development, improves diagnostic reliability, and supports large-scale manufacturing requirements. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | MOLECULAR DIAGNOSTICS (Technology) |
| Forecast Period | 2026-2031 |
| Growth Rate | CAGR of 7.7% from 2026 to 2031 |
| Largest Segment | IVD MANUFACTURERS (End User) |
| Market Size Base Year (Billions) | ~USD 21.46 (2026) |
| Revenue Forecast (Billions) | ~USD 31.1 (2031) |
| Segments Covered | Product Type, Type, Technology, Application, Supply Source, Source/Origin, End User |
7 segment dimensions are covered across the global market.
| Country | 2025 size (native) |
|---|---|
| Germany | USD 1749.2 Million |
| UK | USD 1239.35 Million |
| France | USD 433 Million |
| Italy | USD 362.1 Million |
| Spain | USD 263.7 Million |
| Rest Of Europe | USD 1126.8 Million |
Europe's IVD raw material market is projected to reach $3,241.7 million by 2031, growing from $2,189.9 million in 2026 at an 8.2% CAGR.
Europe's 8.2% CAGR exceeds the global average of 7.7%, demonstrating the region's accelerated demand for diagnostic raw materials and its strategic market importance.
Europe's IVD raw material market operates under CE marking requirements, ISO compliance standards, and stringent quality protocols that ensure consistent safety and efficacy across the supply chain.
Key drivers include aging populations, rising chronic disease prevalence, increased healthcare spending, adoption of point-of-care testing, and Europe's focus on precision medicine and personalized diagnostics.
Europe's established manufacturing capabilities, mature regulatory framework, strong R&D investments, and collaborative ecosystem between manufacturers and suppliers position it as a strategic global IVD raw material hub.
The objective of this study is to analyze the key dynamics influencing the IVD raw material market, including drivers, restraints, opportunities, challenges, and emerging technology trends. The study also evaluates competitive developments, including product launches, regulatory approvals, acquisitions, partnerships, collaborations, and geographic expansions undertaken by leading market participants. Furthermore, it assesses the competitive landscape of the IVD raw material market by profiling key players and benchmarking them across various business and product strategy parameters. Both top-down and bottom-up approaches were employed to estimate the overall market size, while market breakdown and data triangulation methodologies were used to validate the size of individual segments and subsegments and ensure the accuracy of market estimates.
The four steps involved in estimating the market size are as follows:
Secondary research for the IVD raw material market drew on a wide range of credible commercial and regulatory sources, including Bloomberg Business, Factiva, and Dun & Bradstreet for corporate financial and operational data. White papers, scientific publications, annual reports, investor presentations, and SEC filings provided additional context on product pipelines, revenue structures, and market positioning. Regulatory databases were used to track device clearances and approvals in key geographies.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Supply-side primary interviews were conducted with project managers, product managers, sales directors, vice presidents of diagnostics, CEOs, and business development directors at manufacturers of IVD raw material, laboratory automation vendors, and IVD distributors. Demand-side primary interviews covered laboratory directors and clinical pathologists at hospital and reference laboratories, forensic laboratory managers, reproductive health clinic directors, academic research scientists, and procurement officers at pharmaceutical and biotechnology companies.
The following is a breakdown of the primary respondents:

Note: Others include sales, marketing, and product managers.
Companies are classified into tiers based on their total revenues. As of 2025, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.
|
COMPANY NAME |
DESIGNATION |
|
Merck KGaA (Germany) |
Sales Manager |
|
Thermo Fisher Scientific Inc. (US) |
Product Manager |
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the IVD raw material market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
The research methodology used to estimate the market size includes the following:

After arriving at the overall market size using the process described above, the total market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed to validate and complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments of the IVD raw material market. The data was triangulated by examining various factors and trends on the demand and supply sides of the IVD raw material market.
The IVD raw material market is the industry involved in the development, production, and supply of biological, chemical, and synthetic components used in manufacturing in vitro diagnostic (IVD) assays and testing systems. These raw materials include antibodies, antigens, proteins, enzymes, substrates, oligonucleotides, nucleic acids, beads and particles, membranes, labels and detection materials, buffers, diluents, and other specialized reagents that serve as critical building blocks for diagnostic tests. IVD raw materials are utilized across a wide range of diagnostic technologies. These materials play a vital role in ensuring the accuracy, sensitivity, specificity, and reliability of diagnostic tests used to detect, diagnose, screen for, monitor, and prognose health-related conditions.
MarketsandMarkets offers the following customizations for this market report.
Product matrix, which provides a detailed comparison of the product portfolio of each company in the IVD raw material market
Full forecast, segment splits, and company analysis for all IVD Raw Material Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report